CG
CRVS icon

Cutler Group’s Corvus Pharmaceuticals CRVS Stock Holding History

Cutler Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-400
Closed -$6K – 5419
2021
Q4 		$6K Sell
400
-41,400
-99% -$161K ﹤0.01% 4046
2021
Q3 		$95K Buy
+41,800
New +$124K ﹤0.01% 1955
2020
Q4 		– Sell
-5,200
Closed -$3K – 4900
2020
Q3 		$3K Buy
+5,200
New +$20.8K ﹤0.01% 3793

Other funds holding CRVS

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Cutler Group's CRVS Position: Q2 2022 in Review

Cutler Group sold out of Corvus Pharmaceuticals (CRVS) in Q2 2022, closing a stake of 4,700 shares — an estimated $7K sold.

Cutler Group first reported a position in CRVS in Q3 2020 and held it in 7 quarters. The position peaked at $75K in Q3 2021. 47 funds tracked by Wall St. Rank hold CRVS as of Q2 2022.

  • Cutler Group reported no remaining Corvus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Cutler Group sold 4,700 Corvus Pharmaceuticals shares in Q2 2022, an estimated $7K.
  • Cutler Group first reported a position in Corvus Pharmaceuticals in Q3 2020 and held it in 7 quarters.
  • Cutler Group's Corvus Pharmaceuticals position peaked at $75K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2022.

Based on Cutler Group's 13F filing for Q2 2022, filed 4 Aug 2022.